Nexara Health — Health Canada Drug Establishment Licence #3-002896

Comparator supply for NCT06247995

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Sponsor: Novartis Pharmaceuticals (INDUSTRY). Phase: PHASE1, PHASE2. Status: Active Not Recruiting. Countries: United States, Australia, Canada, China, France, Germany, Netherlands, Portugal, Singapore, South Korea, Spain. Last update posted 2026-09-04.

Registry record: https://clinicaltrials.gov/study/NCT06247995.

Canadian-labelled capecitabine

11 marketed Canadian product(s) from 6 manufacturer(s) contain capecitabine. Available strengths: 150 MG, 500 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.

What we supply

Frequently asked questions

Can Nexara supply Canadian-labelled capecitabine as a trial comparator?

Yes. We source Canadian-marketed capecitabine under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT06247995.

What documentation comes with each shipment?

Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.

How long does comparator supply take?

Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.

Request comparator quote

Request comparator quote or call +1-431-588-9055.

Related pages